Redx is a pharmaceutical company that focuses on the discovery and development of small molecule therapeutics. They aim to address unmet medical needs in cancer, fibrosis, and infectious diseases.
Redx was founded in 2010 as a spin-out from the University of Liverpool.
In 2013, Redx acquired the chemistry assets of UCB Pharma, allowing them to expand their drug discovery capabilities.
In 2015, Redx completed an initial public offering and became listed on the London Stock Exchange.
Over the years, Redx has formed collaborations with various organizations, including AstraZeneca and Cancer Research UK, to accelerate the development of their drug candidates.
AstraZeneca is a global pharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. They have a diverse product portfolio in various therapeutic areas, including oncology and respiratory diseases.
Pfizer is a multinational pharmaceutical corporation that develops and produces medicines and vaccines for a wide range of therapeutic areas. They are known for their innovations in areas like oncology, immunology, and rare diseases.
Novartis is a Swiss multinational pharmaceutical company that develops and manufactures a broad range of healthcare products. They have a strong focus on research and development, with a diverse portfolio of medications and therapies.
RXC004 is an oral small molecule compound developed by Redx for the treatment of fibrosis. It targets a specific protein involved in fibrotic pathways, potentially reducing fibrosis progression.
RXC006 is a preclinical drug candidate developed by Redx for the treatment of cancer. It inhibits a specific cellular pathway involved in tumor growth, potentially leading to the suppression of cancer cells.
RXC007 is a novel antibiotic developed by Redx to tackle drug-resistant bacterial infections. It has shown promising activity against certain types of bacteria and may help address the global issue of antibiotic resistance.
Redx is known for its focus on the discovery and development of small molecule therapeutics for cancer, fibrosis, and infectious diseases.
Redx has collaborated with organizations like AstraZeneca and Cancer Research UK to accelerate the development of their drug candidates.
RXC004 targets a specific protein involved in fibrotic pathways, aiming to reduce fibrosis progression.
Redx focuses on addressing unmet medical needs in the areas of cancer, fibrosis, and infectious diseases.
RXC007 is a novel antibiotic developed by Redx that aims to tackle drug-resistant bacterial infections, addressing the global issue of antibiotic resistance.